NASDAQ:GLTO

Galecto (GLTO) Stock Forecast, Price & News

$2.39

+0.13 (+5.75%)

(As of 06/6/2023 ET)

Compare

Today's Range: $2.26
▼
$2.41
50-Day Range: $1.68
▼
$2.66
52-Week Range: $1.04
▼
$2.95

Volume: 57,183 shs
Average Volume: 61,502 shs
Market Capitalization: $61.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.67

Galecto MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 388.1% Upside
$11.67 Price Target
Short Interest: Healthy
0.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$401,514 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.30) to ($2.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

414th out of 981 stocks

Pharmaceutical Preparations Industry

199th out of 460 stocks

3.5

Analyst's Opinion

Consensus Rating
Galecto has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.67, Galecto has a forecasted upside of 388.1% from its current price of $2.39.
Amount of Analyst Coverage
Galecto has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.07% of the float of Galecto has been sold short.
Short Interest Ratio / Days to Cover
Galecto has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Galecto has recently decreased by 3.28%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Galecto does not currently pay a dividend.
Dividend Growth
Galecto does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GLTO.

1.5

News and Social Media Coverage

News Sentiment
Galecto has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
Search Interest
Only 1 people have searched for GLTO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
3 people have added Galecto to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Galecto insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $401,514.00 in company stock.
Percentage Held by Insiders
12.10% of the stock of Galecto is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 35.82% of the stock of Galecto is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Galecto are expected to decrease in the coming year, from ($2.30) to ($2.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Galecto is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Galecto is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Galecto has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Galecto (NASDAQ:GLTO) Stock

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Receive GLTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galecto and its competitors with MarketBeat's FREE daily newsletter.

GLTO Stock News Headlines

May 30, 2023 | finance.yahoo.com

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 25, 2023 | americanbankingnews.com

Galecto, Inc. (NASDAQ:GLTO) Expected to Earn Q1 2024 Earnings of ($0.36) Per Share

June 6, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 24, 2023 | msn.com

HC Wainwright & Co. Reiterates Galecto (GLTO) Buy Recommendation

May 24, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Galecto (GLTO), Bioxcel Therapeutics (BTAI) and Wave Life Sciences (WVE)

May 23, 2023 | finance.yahoo.com

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 20, 2023 | finance.yahoo.com

Companies Like Galecto (NASDAQ:GLTO) Could Be Quite Risky

May 17, 2023 | finance.yahoo.com

Galecto to Present Poster at Upcoming ATS 2023 International Conference

June 6, 2023 | MarketBeat Internal (Ad)

Save $200 on MarketBeat All Access

MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.

May 17, 2023 | americanbankingnews.com

Galecto, Inc. (NASDAQ:GLTO) Forecasted to Post Q2 2023 Earnings of ($0.59) Per Share

May 16, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Galecto (GLTO) with Buy Recommendation

May 15, 2023 | markets.businessinsider.com

Galecto (GLTO) Gets a Buy from H.C. Wainwright

May 15, 2023 | americanbankingnews.com

Galecto (NASDAQ:GLTO) Earns Buy Rating from Analysts at HC Wainwright

April 28, 2023 | finanznachrichten.de

Galecto, Inc.: Galecto Reports First Quarter Operating and Financial Results

April 20, 2023 | americanbankingnews.com

Orbimed Advisors Llc Sells 13,089 Shares of Galecto, Inc. (NASDAQ:GLTO) Stock

April 19, 2023 | americanbankingnews.com

Orbimed Advisors Llc Sells 41,446 Shares of Galecto, Inc. (NASDAQ:GLTO) Stock

April 13, 2023 | finance.yahoo.com

Galecto to Present Two Posters at AACR Annual Meeting 2023

April 13, 2023 | americanbankingnews.com

Galecto, Inc. (NASDAQ:GLTO) Major Shareholder Sells $91,698.12 in Stock

April 10, 2023 | 247wallst.com

Orbimed Advisors Now Owns 10.5% of Galecto

April 8, 2023 | americanbankingnews.com

Galecto, Inc. (NASDAQ:GLTO) Major Shareholder Orbimed Advisors Llc Sells 92,965 Shares

March 21, 2023 | americanbankingnews.com

Galecto (NASDAQ:GLTO) Receives New Coverage from Analysts at Cantor Fitzgerald

March 20, 2023 | nasdaq.com

Cantor Fitzgerald Initiates Coverage of Galecto (GLTO) with Overweight Recommendation

March 9, 2023 | finance.yahoo.com

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

March 4, 2023 | benzinga.com

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

March 2, 2023 | finance.yahoo.com

Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference

February 24, 2023 | nz.finance.yahoo.com

Galecto, Inc. (GLTO) stock price, news, quote & history – Yahoo Finance

February 1, 2023 | finance.yahoo.com

Galecto to Participate in SVB Securities Global Biopharma Conference

See More Headlines

GLTO Price History

30 days | 90 days | 365 days | Advanced Chart

GLTO Company Calendar

Last Earnings: 3/09/2023
Today: 6/06/2023
Next Earnings (Estimated): 8/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLTO
CUSIP: N/A
CIK: 1800315
Web: galecto.com
Phone: 45-7070-5210
Fax: N/A
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.67
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +388.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-61,620,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -85.49%
Return on Assets: -73.78%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.06
Quick Ratio: 4.06

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.41 per share
Price / Book: 0.99

Miscellaneous

Outstanding Shares: 25,670,000
Free Float: 22,567,000
Market Cap: $61.35 million
Optionable: Not Optionable
Beta: 0.74

Key Executives

Dr. Hans T. Schambye M.D. (Age 56)
Ph.D., Co-Founder, Pres, CEO & Director
Comp: $735.2k

Mr. Jonathan P. Freve CPA (Age 44)
CPA, Chief Financial Officer
Comp: $602.4k

Mr. Anders Pedersen (Age 62)
Chief Operating Officer
Comp: $540.39k

Mr. Ulf J. Nilsson
Co-Founder

Dr. Hakon Leffler
Co-Founder

Prof. Tariq Sethi M.D.
B.Sc., M.A., Ph.D., FRCP, Co-Founder & Member of the Clinical Advisory Board - IPF

Mr. Garrett Winslow Esq. (Age 43)
Sr. VP, Gen. Counsel & Corp. Sec.

Prof. Bertil Lindmark M.D. (Age 67)
Ph.D., Chief Medical Officer

Dr. Stephanie Oestreich Ph.D. (Age 48)
Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLTO Stock - Frequently Asked Questions

Should I buy or sell Galecto stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLTO shares.
View GLTO analyst ratings or view top-rated stocks.
What is Galecto's stock price forecast for 2023?: 4 analysts have issued 12 month price targets for Galecto's stock. Their GLTO share price forecasts range from $6.00 to $16.00. On average, they expect the company's share price to reach $11.67 in the next year. This suggests a possible upside of 388.1% from the stock's current price.
View analysts price targets for GLTO or view top-rated stocks among Wall Street analysts.
How have GLTO shares performed in 2023?: Galecto's stock was trading at $1.15 on January 1st, 2023. Since then, GLTO stock has increased by 107.8% and is now trading at $2.39.
View the best growth stocks for 2023 here.
When is Galecto's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our GLTO earnings forecast.
How were Galecto's earnings last quarter?: Galecto, Inc. (NASDAQ:GLTO) announced its quarterly earnings results on Thursday, March, 9th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.02.
What ETF holds Galecto's stock ?: BlackRock Future Health ETF holds 610 shares of GLTO stock, representing 0.02% of its portfolio.

When did Galecto IPO?: (GLTO) raised $86 million in an initial public offering (IPO) on Thursday, October 29th 2020. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and Kempen & Co. was co-manager.
What is Galecto's stock symbol?: Galecto trades on the NASDAQ under the ticker symbol "GLTO."
Who are Galecto's major shareholders?: Galecto's stock is owned by a variety of retail and institutional investors. Top institutional investors include MAI Capital Management (1.00%), Susquehanna International Group LLP (0.25%) and Two Sigma Advisers LP (0.21%). Insiders that own company stock include Bertil Lindmark, Garrett Winslow, Hans T Schambye, Jonathan Freve and Orbimed Advisors Llc.
View institutional ownership trends.
How do I buy shares of Galecto?: Shares of GLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Galecto's stock price today?: One share of GLTO stock can currently be purchased for approximately $2.39.
How much money does Galecto make?: Galecto (NASDAQ:GLTO) has a market capitalization of $61.35 million. The company earns $-61,620,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis.
How can I contact Galecto?: Galecto's mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The official website for the company is galecto.com. The company can be reached via phone at 45-7070-5210.

This page (NASDAQ:GLTO) was last updated on 6/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial